Currently, the inhibitor for pus7 has been identified to reduce Ψ levels of tRNA and inhibit GBM tumorigenesis and growth, providing potential therapeutic drugs for targeting PUS7 in GBM and other cancers130. Here, PUS7 is linked to glioblastoma.